Drugmaker Allergan PLC’s flagship Botox got FDA approval for use in treating lower limb spasticity in children, except those with cerebral palsy.

The drug, a neurotoxin best-known for treating wrinkles, has received multiple indications over the years because of how it works on the body.

Botox accounted for about $3.6 billion in annual sales for Allergan as part of the Dublin-based company’s aesthetics division, based in Irvine.

Allergan is being bought by Chicago-based AbbVie Inc. for $63 billion, in a deal expected to close in early 2020.

For more on the new use of Botox and other pharma news, see the Nov. 4 print edition of the Business Journal